肺动脉高压常用靶向药物与肺动脉去神经术治疗效果的对比：一项系统综述

Efficacy of Commonly Targeted Drugs versus Pulmonary Artery Denervation for Pulmonary Hypertension: A Systematic Review

摘要: 目的：目前肺动脉高压的主要治疗方式仍为药物治疗，近年来新兴一种肺动脉去神经术以治疗肺动脉高压。本文旨在研究肺动脉高压常用靶向药物与肺动脉去神经术治疗效果及其治疗效果的对比。方法：两位研究者进行了独立、全面的文献检索。搜索了Pubmed、Embase以及灰色文献数据库OpenGray。两位研究者没有出现分歧。结果：纳入15篇相关文献，对其进行质量评价及关键信息提取。结论：波生坦、伊洛前列素、肺动脉去神经术都对肺动脉高压严重程度评估的各项指标如六分钟步行距离、平均肺动脉压、肺血管阻力等指标有明显改善。但对延缓患者临床恶化的时间及减轻临床恶化的严重程度的效果尚不太明确。当前以肺动脉高压患者为研究对象的肺动脉去神经术相关的随机对照实验还较少，本研究并不能证明其在治疗肺动脉高压方面明显强于药物治疗。

Abstract: Objective: At present, the main treatment for pulmonary hypertension is still drug therapy. In re-cent years, pulmonary artery denervation is a new treatment for pulmonary hypertension. The ob-jective of this study was to compare the therapeutic effects of commonly used targeted drugs and pulmonary denervation for pulmonary hypertension. Methods: Two researchers conducted an in-dependent and comprehensive literature search. Pubmed, Embase and grey literature database OpenGray were searched. There is no disagreement between the two researchers. Results: Fifteen related literatures were included, and their quality was evaluated and key information was ex-tracted. Conclusions: Bosentan, Iloprost, and pulmonary artery denervation significantly reduced the severity of pulmonary hypertension, including 6-minute walking distance, mean pulmonary ar-terial pressure, and pulmonary vascular resistance etc. However, the effect of delaying the time of Clinical deterioration and reducing the severity of clinical deterioration is not clear. Currently, there are few randomized controlled trials related to pulmonary artery denervation in patients with pulmonary hypertension, and this study cannot prove that pulmonary artery denervation is signif-icantly superior to drug therapy in the treatment of pulmonary hypertension.